{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:21:27Z","timestamp":1788531687361,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":233,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The conversion of native prion protein (PrP) into its misfolded isoform, scrapie (PrPSc) and its intracellular accumulation represent central events in the pathogenesis of prion diseases. Reduction of native PrP in the central nervous system (CNS) has emerged as a promising strategy for treatment and prevention of prion diseases in humans. To facilitate translation into clinical practice, it is essential to identify at-risk individuals through biomarker development and to elucidate PrP behaviour across prion disease subtypes and biological fluids. Measurements of PrP in accessible biofluids, such as plasma and cerebrospinal fluid (CSF), may provide a pharmacodynamic readout and enable monitoring for PrP-targeted therapies. This study systematically quantifies PrP in plasma and CSF of individuals with sporadic and genetic prion diseases, healthy controls (HC), patients with non-neurodegenerative neurological conditions (ND) and Alzheimer\u2019s disease (AD). We analysed 136 plasma and 84 CSF samples, including HC, AD, sporadic Creutzfeldt\u2013Jakob disease (sCJD), as well as symptomatic patients and asymptomatic carriers of the mutations D178N, E200K and P102L. Quantification of PrP was performed using a BetaPrion Human ELISA. Statistical analyses assessed differences between diagnostic groups, associations with demographic factors and PRNP codon 129 polymorphism, and diagnostic accuracy via ROC curves. Plasma PrP was significantly reduced in patients with sCJD (P = 0.043), in symptomatic patients with the E200K (P = 0.0078) and in both symptomatic and asymptomatic D178N carriers (P = 0.0002) compared to HC. Furthermore, symptomatic and asymptomatic D178N carriers had significantly lower plasma PrP levels than patients with AD (P = 0.0025 and P = 0.0041, respectively). In CSF, PrP concentrations were notably lower in D178N symptomatic patients (P = 0.0026) versus non-neurodegenerative (ND) controls. Plasma PrP levels showed no association with age, sex or disease onset and were lower in genetic prion disease patients with the methionine\/valine (MV) genotype at PRNP codon 129. The diagnostic accuracy for PrP quantification in plasma as a biomarker discriminated D178N asymptomatic carriers [area under the curve (AUC) = 0.96] and D178N symptomatic patients (AUC = 0.90) from HC with excellent accuracy. In CSF, PrP quantification discriminated D178N symptomatic patients from ND with good accuracy (AUC = 0.64). Taken together, this study defines a characteristic profile of persistently low plasma and CSF PrP in D178N symptomatic and asymptomatic mutation carriers. Low plasma levels in sCJD and E200K, in contrast to P102L, are puzzling. Mutation-specific patterns of PrP need to be considered for monitoring purposes in clinical trials.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag321","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:47:59Z","timestamp":1787226479000},"source":"Crossref","is-referenced-by-count":0,"title":["Prion protein (PrP) profiles in blood and CSF: insights into pre-symptomatic and symptomatic prion disease"],"prefix":"10.1093","volume":"8","author":[{"given":"In\u00eas","family":"Laginha","sequence":"first","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-681X","authenticated-orcid":false,"given":"Matthias","family":"Schmitz","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngela","family":"da Silva Correia","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyaba","family":"Saleem","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE) , Cooperation Unit Translational studies and biomarker, 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"da Silva Correia","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4261-0339","authenticated-orcid":false,"given":"Saima","family":"Zafar","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Younas","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezgi","family":"Canaslan","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Root","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Breitbarth","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lisa","family":"Fischer","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dittmar","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"\u017dakova","sequence":"additional","affiliation":[{"name":"National Reference Center for Prion Diseases and Slow Viral Infections, Slovak Medical University , 833 03 Bratislava ,","place":["Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hermann","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[{"name":"National Reference Center for CJD Surveillance, Department of Neurology, University Medical Center , 37075 G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE) , Cooperation Unit Translational studies and biomarker, 37075 G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"23","key":"2026090409412016100_fcag321-B1","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026090409412016100_fcag321-B2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1471-4159.2006.03909.x","article-title":"Prion diseases of humans and farm animals: Epidemiology, genetics, and pathogenesis","volume":"97","author":"Aguzzi","year":"2006","journal-title":"J Neurochem"},{"issue":"4","key":"2026090409412016100_fcag321-B3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/GIM.0b013e3181cd7374","article-title":"The genetics of prion diseases","volume":"12","author":"Mastrianni","year":"2010","journal-title":"Genet Med"},{"issue":"1","key":"2026090409412016100_fcag321-B4","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2016.5.FOCUS15126","article-title":"Human prion diseases: Surgical lessons learned from iatrogenic prion transmission","volume":"41","author":"Bonda","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"3","key":"2026090409412016100_fcag321-B5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","article-title":"Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease","volume":"20","author":"Hermann","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026090409412016100_fcag321-B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.410430109","article-title":"Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease","volume":"43","author":"Zerr","year":"1998","journal-title":"Ann Neurol"},{"issue":"3","key":"2026090409412016100_fcag321-B7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0304-3940(97)00215-2","article-title":"Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"225","author":"Otto","year":"1997","journal-title":"Neurosci Lett"},{"issue":"3","key":"2026090409412016100_fcag321-B8","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s12035-017-0479-5","article-title":"Validation of alpha-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease","volume":"55","author":"Llorens","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"2","key":"2026090409412016100_fcag321-B9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","article-title":"Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion","volume":"17","author":"Atarashi","year":"2011","journal-title":"Nat Med"},{"key":"2026090409412016100_fcag321-B10","doi-asserted-by":"crossref","first-page":"38737","DOI":"10.1038\/srep38737","article-title":"Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease","volume":"6","author":"Steinacker","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"2026090409412016100_fcag321-B11","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s12035-015-9167-5","article-title":"Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic","volume":"53","author":"Schmitz","year":"2016","journal-title":"Mol Neurobiol"},{"issue":"2","key":"2026090409412016100_fcag321-B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1474-4422(25)00406-5","article-title":"Advances in biomarkers for diagnosis and prognosis of prion diseases","volume":"25","author":"Zerr","year":"2026","journal-title":"Lancet Neurol"},{"issue":"6","key":"2026090409412016100_fcag321-B13","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/brain\/awad101","article-title":"Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease","volume":"146","author":"Mok","year":"2023","journal-title":"Brain"},{"issue":"4","key":"2026090409412016100_fcag321-B14","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s12035-018-1251-1","article-title":"Cerebrospinal fluid total prion protein in the spectrum of prion diseases","volume":"56","author":"Villar-Pique","year":"2019","journal-title":"Mol Neurobiol"},{"issue":"12","key":"2026090409412016100_fcag321-B15","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-019-09537-0","article-title":"Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC","volume":"266","author":"Abu-Rumeileh","year":"2019","journal-title":"J Neurol"},{"issue":"4","key":"2026090409412016100_fcag321-B16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1537-2995.2001.41040441.x","article-title":"Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases","volume":"41","author":"Volkel","year":"2001","journal-title":"Transfusion"},{"issue":"3","key":"2026090409412016100_fcag321-B17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/nan.12573","article-title":"Plasma total prion protein as a potential biomarker for neurodegenerative dementia: Diagnostic accuracy in the spectrum of prion diseases","volume":"46","author":"Llorens","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2026090409412016100_fcag321-B18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-020-01608-8","article-title":"Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease","volume":"18","author":"Vallabh","year":"2020","journal-title":"BMC Med"},{"issue":"2","key":"2026090409412016100_fcag321-B19","doi-asserted-by":"crossref","first-page":"e209506","DOI":"10.1212\/WNL.0000000000209506","article-title":"Fluid biomarkers in individuals at risk for genetic prion disease up to disease conversion","volume":"103","author":"Vallabh","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"2026090409412016100_fcag321-B20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.sbi.2008.12.007","article-title":"Prion protein misfolding and disease","volume":"19","author":"Moore","year":"2009","journal-title":"Curr Opin Struct Biol"},{"issue":"6","key":"2026090409412016100_fcag321-B21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/j.1460-2075.1996.tb00467.x","article-title":"Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie","volume":"15","author":"Fischer","year":"1996","journal-title":"EMBO J"},{"issue":"9","key":"2026090409412016100_fcag321-B22","doi-asserted-by":"crossref","first-page":"102381","DOI":"10.1016\/j.jbc.2022.102381","article-title":"Central residues in prion protein PrP(C) are crucial for its conversion into the pathogenic isoform","volume":"298","author":"Pasiana","year":"2022","journal-title":"J Biol Chem"},{"issue":"7","key":"2026090409412016100_fcag321-B23","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0092-8674(93)90360-3","article-title":"Mice devoid of PrP are resistant to scrapie","volume":"73","author":"Bueler","year":"1993","journal-title":"Cell"},{"issue":"4","key":"2026090409412016100_fcag321-B24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41591-024-03466-w","article-title":"In vivo base editing extends lifespan of a humanized mouse model of prion disease","volume":"31","author":"An","year":"2025","journal-title":"Nat Med"},{"issue":"29","key":"2026090409412016100_fcag321-B25","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1073\/pnas.0802759105","article-title":"Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease","volume":"105","author":"White","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026090409412016100_fcag321-B26","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1038\/mtna.2011.6","article-title":"Intracerebral infusion of antisense oligonucleotides into prion-infected mice","volume":"1","author":"Nazor Friberg","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"2026090409412016100_fcag321-B27","doi-asserted-by":"crossref","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"5","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"issue":"19","key":"2026090409412016100_fcag321-B28","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2026090409412016100_fcag321-B29","doi-asserted-by":"crossref","first-page":"e88797","DOI":"10.1371\/journal.pone.0088797","article-title":"Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder","volume":"9","author":"Lehmann","year":"2014","journal-title":"PLoS One"},{"issue":"24","key":"2026090409412016100_fcag321-B30","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2026090409412016100_fcag321-B31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090409412016100_fcag321-B32","author":"Ionis Pharmaceuticals I"},{"issue":"9","key":"2026090409412016100_fcag321-B33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.neurol.2025.08.004","article-title":"Tracing neurological diseases in the presymptomatic phase: Moving forward a detection panel","volume":"181","author":"Rival","year":"2025","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"2026090409412016100_fcag321-B34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00415-025-13432-2","article-title":"Pedigree analysis and genetic inheritance of fatal familial insomnia (FFI) in a Portuguese multigenerational family","volume":"272","author":"Da Silva Correia","year":"2025","journal-title":"J Neurol"},{"issue":"4","key":"2026090409412016100_fcag321-B35","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/trc2.70013","article-title":"Application of the revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Drug development and clinical practice","volume":"10","author":"Jack","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"2026090409412016100_fcag321-B36","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2026090409412016100_fcag321-B37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00439-005-0020-1","article-title":"Genetic prion disease: The EUROCJD experience","volume":"118","author":"Kovacs","year":"2005","journal-title":"Hum Genet"},{"issue":"3","key":"2026090409412016100_fcag321-B38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jnr.21142","article-title":"Cellular prion protein is increased in the plasma and peri-infarcted brain tissue after acute stroke","volume":"85","author":"Mitsios","year":"2007","journal-title":"J Neurosci Res"},{"issue":"2","key":"2026090409412016100_fcag321-B39","doi-asserted-by":"crossref","first-page":"e0117286","DOI":"10.1371\/journal.pone.0117286","article-title":"Plasma soluble prion protein, a potential biomarker for sport-related concussions: A pilot study","volume":"10","author":"Pham","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2026090409412016100_fcag321-B40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2009.04.025","article-title":"Transport of prion protein across the blood-brain barrier","volume":"218","author":"Banks","year":"2009","journal-title":"Exp Neurol"},{"key":"2026090409412016100_fcag321-B41","doi-asserted-by":"crossref","first-page":"874734","DOI":"10.3389\/fnagi.2022.874734","article-title":"The use of real-time quaking-induced conversion for the diagnosis of human prion diseases","volume":"14","author":"Poleggi","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2026090409412016100_fcag321-B42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/v14020276","article-title":"Total and phosphorylated cerebrospinal fluid tau in the differential diagnosis of sporadic Creutzfeldt-Jakob disease and rapidly progressive Alzheimer\u2019s disease","volume":"14","author":"Hermann","year":"2022","journal-title":"Viruses"},{"issue":"3","key":"2026090409412016100_fcag321-B43","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1750-3639.1998.tb00176.x","article-title":"Molecular pathology of fatal familial insomnia","volume":"8","author":"Parchi","year":"1998","journal-title":"Brain Pathol"},{"issue":"21","key":"2026090409412016100_fcag321-B44","doi-asserted-by":"crossref","first-page":"12661","DOI":"10.1074\/jbc.271.21.12661","article-title":"Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein","volume":"271","author":"Petersen","year":"1996","journal-title":"J Biol Chem"},{"issue":"3","key":"2026090409412016100_fcag321-B45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamaneurol.2014.4068","article-title":"Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease","volume":"72","author":"Dorey","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"2026090409412016100_fcag321-B46","doi-asserted-by":"crossref","first-page":"e156532","DOI":"10.1172\/jci.insight.156532","article-title":"Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS","volume":"7","author":"Mortberg","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"2026090409412016100_fcag321-B47","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1074\/mcp.RA119.001702","article-title":"Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry","volume":"18","author":"Minikel","year":"2019","journal-title":"Mol Cell Proteomics"},{"key":"2026090409412016100_fcag321-B48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2021.09.010","article-title":"Plasma cellular prion protein concentrations correlate with severity and prognosis of aneurysmal subarachnoid hemorrhage","volume":"523","author":"Yao","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2026090409412016100_fcag321-B49","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.neurobiolaging.2013.11.010","article-title":"Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic or familial prion diseases","volume":"35","author":"Schmitz","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"26","key":"2026090409412016100_fcag321-B50","doi-asserted-by":"crossref","first-page":"14955","DOI":"10.1073\/pnas.011578098","article-title":"Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation","volume":"98","author":"Ma","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"41","key":"2026090409412016100_fcag321-B51","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1074\/jbc.RA118.002754","article-title":"Overexpression of quality control proteins reduces prion conversion in prion-infected cells","volume":"293","author":"Thapa","year":"2018","journal-title":"J Biol Chem"},{"issue":"24","key":"2026090409412016100_fcag321-B52","doi-asserted-by":"crossref","first-page":"21732","DOI":"10.1074\/jbc.M213247200","article-title":"Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation","volume":"278","author":"Drisaldi","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"2026090409412016100_fcag321-B53","doi-asserted-by":"crossref","first-page":"e1000479","DOI":"10.1371\/journal.ppat.1000479","article-title":"Selective processing and metabolism of disease-causing mutant prion proteins","volume":"5","author":"Ashok","year":"2009","journal-title":"PLoS Pathog"},{"issue":"4","key":"2026090409412016100_fcag321-B54","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.neuron.2008.09.008","article-title":"Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model","volume":"60","author":"Dossena","year":"2008","journal-title":"Neuron"},{"key":"2026090409412016100_fcag321-B55","author":"Correia"},{"issue":"6","key":"2026090409412016100_fcag321-B56","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/labinvest.2009.30","article-title":"Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease","volume":"89","author":"Choi","year":"2009","journal-title":"Lab Invest"},{"key":"2026090409412016100_fcag321-B57","doi-asserted-by":"crossref","first-page":"105306","DOI":"10.1016\/j.neuint.2022.105306","article-title":"CSF biomarkers for prion diseases","volume":"155","author":"Satoh","year":"2022","journal-title":"Neurochem Int"},{"issue":"1","key":"2026090409412016100_fcag321-B58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-021-00815-6","article-title":"Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease","volume":"13","author":"Zerr","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"14","key":"2026090409412016100_fcag321-B59","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra2119323","article-title":"Laboratory diagnosis of Creutzfeldt-Jakob disease","volume":"386","author":"Zerr","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2026090409412016100_fcag321-B60","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00415-009-5163-x","article-title":"Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies","volume":"256","author":"Ladogana","year":"2009","journal-title":"J Neurol"},{"issue":"16","key":"2026090409412016100_fcag321-B61","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1073\/pnas.1901947116","article-title":"Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development","volume":"116","author":"Vallabh","year":"2019","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag321\/70760014\/fcag321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag321\/70760014\/fcag321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/5\/fcag321\/70760014\/fcag321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:41:33Z","timestamp":1788529293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag321\/8767971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag321","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag321"}}